Plain-English translation of NCT07311408 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether a combination of three medications—SHR-1701, Rivoceranib, and SHR-2554—can help people whose gastric or gastroesophageal junction cancer has progressed or stopped responding to first-line immunotherapy. Some participants will receive all three medications, while others will receive just two of them. The goal is to see if the treatment can slow cancer growth and improve survival.
When gastric cancer stops responding to initial immunotherapy, patients have limited treatment options. This trial is exploring whether combining medications that work through different mechanisms might help patients whose cancer has become resistant to first-line treatment.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of two groups: one receiving all three medications, and the other receiving two medications. You will receive one of the medications as an intravenous infusion every 3 weeks, and the other medication(s) as pills taken by mouth daily. You will need regular clinic visits for scans, blood work, and check-ups to monitor how well the treatment is working and to watch for any side effects. The study will track how long your cancer stays stable and whether the tumors shrink.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Jingdong Zhang
Enrollment target
~40 participants
Started
January 2026
Primary completion
January 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in December 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Qian Dong, Doctor
Jingdong Zhang
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.